Hi Keystone. Thanks. I appreciate your continuing efforts here There is obviously a large psychological component to all of this for AMRN investors. All are looking for the upward trend. I realize that Tuesday was Veteran's day and likely impacted the numbers . I see that Lovaza and Generic Lovaza are down as well, so it isn't just Vascepa. Have a good day.
TR x: 9607 (down from 9880 prior week)
NR x: 4233 (down from 4341)
(RECALL that Tuesday 11/11/14 was Veteran's Day and likely impacted these numbers.)
TR x:......25,220 (down from 26,865)......53,092 (down from 54,863)
NR x: ....7,531 (down from 7,848)...........23,862 (down from 24,451)
Yeah and I put that fraud of a poster in his place like you. He was spouting off about a triple level buyout stock offer that was going to be impossible to achieve. Of course he lost the argument from many other posters not just me. His maturity level showed through with his replys and they just weren't to me. Please give me some concrete data to back up your claims about these numbers you have put together that a BP will offer Amrn. Then maybe I won't give you such a hard time!
Probably $6 low end price target. Once label changes come into play $11 is the price after Reduce it $38. Just expect sharp increase in price. Warrants are at $2.58 its upto buyer if they want to cash them out at $2.58.
I doubt they will sell less then $11.
Sentiment: Strong Buy
It appears Jon Plexico has been laying some money down recently on speculative biotech stocks. In addition to Stonepine's purchase on Tuesday, he purchased roughly 2.8 million shares of Pain Therapeutics on October 31st.. Pfizer chose to discontinue an agreement with Pain Therapeutics to develop and commercialize Remoxy Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. When Pfizer decided to return all rights on Oct. 27 including responsibility for regulatory activities, the company tanked 53%. It appears Stonepine sees this as a speculative play. In addition, Jon Plexico has purchased 1.7 million shares of Aastrom Biosciences in Sept. I'm familiar with ASTM as they were a bio tissue company with headquarters in Ann Arbor, MI. Interesting, ASTM has announced they are changing their name and moving east. It's obvious Stonepine has recently targeted small speculative biotech companies they see as undervalued. I'm sure they have done significant DD and it will be interesting to see how the AMRN sNDA plays-out in the next several months.
You will never get your money back. And if you still have your money in AMRN, it is your own %$#@ fault.
Statins could become extinct.
Omega 3 supplements like Vascepa and Lovaza and Omegavia will also be made obsolete.
It is very exciting for anybody worried about Cardiovascular issues.
fjest , quick response
Immediate risk on the horizon is whether or not AZN launchs Epanova.
I don't believe AMRN mgt when these say they are not concerned
If AZN does NOT launch its great for AMRN because it probably means that Amarins patents are very strong
Re Niacin / fibrates etc ...these are cardiovascular drugs aimed at raising HDL and lowering LDL in the Anchor market . The Marine market is more about the risk of Pancreatitis . In that market Lovaza is recognized as the best to lower TG's over 750 the furthest ...the problem being the raise in LDL.
Statins can control the LDL in this market but if patient is Statin intolerant ( about 20% ) Vascepa is the best option
We need AMRN to make it to interim analysis and that analysis to be good enough to stop RI for efficacy
Then Vascepa will dominate the mixed D and RI markets ...which are huge.
Thats why I'm long AMRN . Don't think they will make it on the Marine market alone